David M Nathan, John M Lachin, Ionut Bebu, Henry B Burch, John B Buse, Andrea L Cherrington, Stephen P Fortmann, Jennifer B Green, Steven E Kahn, M Sue Kirkman, Heidi Krause-Steinrauf, Mary E Larkin, Lawrence S Phillips, Rodica Pop-Busui, Michael Steffes, Margaret Tiktin, Mark Tripputi, Deborah J Wexler, Naji Younes
BACKGROUND: Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes. METHODS: We assessed the comparative effectiveness of four commonly used glucose-lowering medications, added to metformin, in achieving and maintaining a glycated hemoglobin level of less than 7.0% in participants with type 2 diabetes...
September 22, 2022: New England Journal of Medicine